Cetigran

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cetigran

Property Description
Active ingredient Cetirizine Dihydrochloride
Pharmacological class Antihistamine (Second-generation)
Origin Synthetic compound (derivative of hydroxyzine)
Forms Tablet, oral solution, syrup, drops
Primary action Selective H1-receptor antagonist

What Type of Medicine is Cetigran?

The medicinal entity Cetigran is the trade name for a product containing the active ingredient Cetirizine Dihydrochloride, and it is primarily classified as an antihistamine. It belongs specifically to the second-generation antihistamine group, a distinction clinically recognized for having enhanced selectivity compared to older compounds. This newer classification indicates the drug is structurally designed for increased receptor selectivity, resulting in focused action for common symptomatic relief needs.

The active compound is a synthetic compound derived from hydroxyzine, and its core pharmacological function is to act as a selective peripheral H1-receptor antagonist. This classification signifies that the substance is engineered to interact exclusively with specific histamine receptors, blocking their activation in the body.

Composition and Available Forms of Cetirizine

The preparation is formulated as a single-active ingredient product (monotherapy) intended solely for oral administration. The substance is widely available in various dosage forms, including the standard tablet, as well as liquid formats such as syrup, oral solution, and drops. The liquid formulations are often specifically positioned toward the pediatric population.

This variation in forms allows the medicine to be adapted for different patient needs. For instance, Cetirizine is used in multiple forms, including drops and solutions, which is vital for use in younger individuals. Whether composed with a solid excipient matrix or an aqueous solution base, the effective component remains the chemical entity, Cetirizine Dihydrochloride.

General Purpose and Mechanism Summary

The general purpose of Cetigran is to provide symptomatic relief by opposing the chemical processes associated with hypersensitivity reactions. Its core function is achieved through the highly specific antagonism of peripheral H1-receptors.

This chemical action limits the development of exaggerated physical responses. By serving as a selective H1-receptor blocker, the medication helps stabilize the body's reaction and broadly addresses conditions rooted in histamine-mediated responses, providing relief in scenarios such as seasonal discomfort.

What side effects are possible with Cetigran?

Possible Side Effects and Safety Information

The official safety information for Cetirizine Dihydrochloride (Cetigran) is structured according to regulatory standards, classifying adverse events by frequency and the body system affected (System-Organ Class or SOC). The data is derived from clinical trials and post-marketing surveillance.

Adverse Reactions Classified by Frequency

Adverse reactions that are frequently documented in official labeling include those classified as Common (occurring in 1 to 10 users in 100). These typically involve Nervous System Disorders and Gastrointestinal Disorders, listing effects such as somnolence (drowsiness), headache, fatigue, and dry mouth. Reactions classified as Uncommon include pruritus (itching) and rash.

Classification Examples of Reactions (SOC)
Common Somnolence, Headache, Dry mouth, Fatigue
Rare Tachycardia, Convulsions, Abnormal liver function, Hypersensitivity reactions
Very Rare Anaphylactic shock, Thrombocytopenia, Hepatitis, Oculogyration

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights rare but clinically significant events. Reactions classified as Rare or Very Rare include severe hypersensitivity (such as Angioneurotic edema or Anaphylactic shock) and signs of abnormal hepatic function, including Hepatitis.

Safety constraints in regulatory documents address specific populations: the medicine is generally contraindicated for individuals with severe renal impairment (very low creatinine clearance). Furthermore, caution is advised for patients with predisposing factors for urinary retention. Post-marketing reports have noted that the sudden cessation of daily use may, in some cases, result in intense rebound pruritus or urticaria.

This framework ensures the formally recognized risks, ranging from common side effects to rare severe reactions and specific population constraints, are clearly communicated.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Cetirizine Dihydrochloride (Cetigran) is officially documented by regulatory agencies to involve manifestations primarily related to the Central Nervous System (CNS). Documented overdose presentations often include somnolence, stupor, dizziness, headache, and a general feeling of malaise. The cardiovascular system may also be affected, evidenced by tachycardia (fast heart rate).

The regulatory labeling mandates that individuals seek immediate medical attention for any suspected overdose. This requirement is critical because no specific antidote is known for Cetirizine Dihydrochloride overdose. Treatment, therefore, is defined as symptomatic and supportive.

Population-specific notes exist for pediatric patients, who may initially exhibit paradoxical signs like restlessness and irritability before the onset of drowsiness. In severe cases, the potential for confusion and the need for close cardiac monitoring are officially noted. Supportive measures mentioned in official documents that may be considered to limit absorption include gastric lavage or the administration of activated charcoal. Hemodialysis is officially noted as being ineffective for drug removal. These steps collectively define the official emergency profile based strictly on regulatory guidance.

Therapeutic Uses of Cetigran

Cetigran is used to provide supportive symptomatic relief across key domains where symptoms are related to heightened physiological activity. It is relevant in clinical settings marked by the sudden onset of symptoms or in conditions that involve fluctuating, recurrent patient distress. It may be part of symptomatic management for its primary indications.


Easing Seasonal and Perennial Allergy Symptoms

This domain covers the upper respiratory and ocular discomfort caused by inhaled allergens throughout the year. Cetigran is commonly applied in conditions like Seasonal Allergic Rhinitis (hay fever) and Perennial Allergic Rhinitis. It plays a role in managing symptoms such as sneezing, runny nose (rhinorrhea), and the intense itching and watering of the eyes (allergic conjunctivitis). The primary therapeutic support is focused on easing the overall symptom burden, helping improve day-to-day comfort during symptomatic periods.

“This medication is commonly used when symptoms create noticeable interference with daily stability, offering assistance during phases of increased distress.”


Managing Chronic Urticaria and Allergic Itching

This therapeutic cluster addresses allergic skin issues, primarily Chronic Urticaria (hives). It is used for managing the intensity of distressing manifestations like widespread itching (pruritus) and the appearance of red, raised skin wheals. It assists with maintaining functional stability and offers symptomatic relief that may help patients cope more steadily with symptom fluctuations, especially when skin symptoms create noticeable interference with daily stability. The conditions it is commonly used for include perennial rhinitis, seasonal rhinitis, and chronic urticaria.

Quick Fact: Symptomatic Relief for Allergic Pruritus

Regulatory References

  1. Cetirizine - StatPearls - NCBI Bookshelf - NIH

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cetigran

Official regulatory documents define the allowed and restricted populations for Cetirizine Dihydrochloride (Cetigran) based on age, organ function, and specific pre-existing conditions.


Category Contraindication / Restriction
Absolute Contraindication Patients with a known hypersensitivity to the drug, its excipients, hydroxyzine, or any piperazine derivatives. Patients with Severe Renal Impairment (Creatinine Clearance <10 mL/min) are excluded.
Age-Related Rules Use is approved for Adults and Adolescents (ge 12 years). Children as young as 6 months are eligible for liquid formulations under specific indications, but the tablet formulation is not recommended for children under 6 years.
Conditional Use Patients with Renal Impairment (CrCL 10–79 mL/min) are eligible, but the official label mandates a dose reduction. Caution is advised for patients with factors predisposing to urinary retention or those with epilepsy/convulsion risk.
Physiological Status Pregnancy and Lactation status require conditional use, and caution should be exercised; use during breastfeeding is often not recommended due to excretion into breast milk.

These constraints establish the official regulatory profile: the medicine is prohibited for those with specific allergies or profound kidney failure, while other groups, such as children and patients with reduced kidney function, have officially documented eligibility limitations and require special consideration.

What should I know about interactions with other medicines?

The regulatory profile for Cetirizine Dihydrochloride (Cetigran) details specific interactions, which are predominantly structured around pharmacodynamic effects and altered drug clearance.


Documented Interaction Patterns

Substance Category Officially Documented Interaction Outcome Classification
Central Nervous System (CNS) Depressants Co-administration may cause additional reductions in alertness and impairment of CNS performance, including sedatives and tranquilizers. Pharmacodynamic
Alcohol Consumption should be avoided as it may increase drowsiness and further impair CNS performance. Substance Restriction
Theophylline (400 mg dose) Results in a 16% decrease in the clearance of cetirizine, a pharmacokinetic interaction that increases exposure. Pharmacokinetic
P-glycoprotein (P-gp) Inhibitors Potential for increased central nervous system exposure as Cetirizine is officially noted as a P-gp substrate. Transporter Pathway

Interaction-Related Restrictions and Considerations

Formally, the medicine is contraindicated in patients with a known hypersensitivity to the parent compound, Hydroxyzine, or to any piperazine derivatives. Caution is officially documented for patients with liver or kidney disease, particularly severe renal impairment (creatinine clearance < 10 mL/min), which is a formal contraindication. This caution is due to the potential for reduced clearance, which can lead to increased drug exposure and interaction effects. Official studies indicate that no clinically significant pharmacokinetic interactions were observed with common medications such as Azithromycin, Erythromycin, Ketoconazole, or Pseudoephedrine. The overall profile focuses on the risk of additive sedative effects and specific pharmacokinetic changes.

Mechanism of Action

How Cetigran Works

Cetigran functions through the modulation of key molecular pathways via targeted interaction with specific molecular receptors and regulatory enzymes. It is classified as an antagonist or selective inhibitor that alters the activity of these specific molecular targets, thereby influencing mechanisms that govern signaling intensity and throughput within biological systems.

The interaction results in changes to the system's sensitivity to circulating mediators. This mechanism reduces the concentration or functional effect of mediators, resulting in a net decrease in pathway activation. Cetigran initiates or suppresses specific signaling sequences, modifying early molecular steps that shape systemic physiological outcomes. This altered signal transmission and mediator concentration kinetics leads to modification of systemic physiological parameters, aligning with its pharmacodynamic profile.

Dosage and Administration Information

Official Route and General Administration

The medicinal product containing Cetirizine Dihydrochloride is primarily administered via the oral route, available in several formulations including tablets, oral solution, and drops. An intravenous (IV) injection formulation is also approved for use by healthcare professionals in specific acute clinical settings. The oral forms can be consumed with or without food, and administration is often suggested once daily in the evening.

Standard Dosing and Frequency

The standardized regimen for adults and adolescents is 10 mg taken once daily, which represents the maximum recommended dose within a 24-hour period. Dosing for less severe symptom patterns may begin at 5 mg once daily. While once-daily use is standard for adults, pediatric regimens may be administered in two divided doses daily to maintain symptom coverage, with maximum doses varying by age group (e.g., 5 mg total daily for children 2 to 5 years).

Population Adjustments and Procedural Rules

Standard protocols indicate that the dosing schedule must be modified for patients with impaired renal function. This often requires reducing the dose to 5 mg once daily or once every two days, depending on the degree of impairment. For oral solution or drops, a calibrated measuring device must be utilized to ensure dose accuracy. If a dose is missed, the general instruction is to skip the forgotten dose and maintain the regular schedule; a double dose should not be taken to compensate. The medicine is utilized for both short-term (as-needed) and long-term continuous administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cetigran

The clinical evaluation of Cetigran (Cetirizine Dihydrochloride) is supported by findings from a range of formal research, including randomized controlled trials (RCTs) and systematic scientific reviews. This body of evidence describes the study context, the types of outcomes measured, and the patient groups that have been observed, without providing individual medical guidance or making claims about personal outcomes.


Evidence for Use in Seasonal and Perennial Allergies

Research exploring Cetigran for conditions characterized by fluctuating or episodic manifestations—such as seasonal hay fever (rhinitis) and associated eye symptoms—primarily relies on short-term randomized controlled trials and systematic reviews. Studies monitored outcomes reflecting daily functioning or activity level using Total Symptom Scores (TSS) and other validated scales. Findings describing patterns observed in the studies regarding outcomes related to episodic or acute changes were documented when compared to placebo or other similar medicines. What remains unclear is the long-term characterization of these outcomes, as the follow-up durations were limited in many primary studies.


Evidence for Use in Chronic Urticaria (Hives)

Studies involving conditions marked by functional limitations—such as widespread itching and raised skin wheals—include Randomized Controlled Trials (RCTs). Research explored outcomes related to systemic or functional imbalance by measuring changes in Urticaria Activity Scores (UAS) and patient-reported outcomes describing perceived discomfort. Observed populations included adults and specific groups of patients whose symptoms were previously observed in research to have insufficient symptom change with standard doses. Data show patterns related to the varying success of increasing the dose in individuals with refractory hives. A key limitation is that sample sizes were modest in specialized research exploring the study of higher-than-standard dosages, and data for certain groups remain insufficient.


Studies in Specific Patient Groups and Uncertainties

Cetigran was evaluated in studies that included pediatric populations (spanning infants as young as 6 months) and older adults. However, research describing the study of higher-than-standard dosages remains insufficient in both older adults and specific subgroups of pediatric patients. The results apply only to the populations studied, and subgroup findings are uncertain. The overall evidence quality varies across studies, and comparative evidence is lacking for a full assessment against every single similar medication available.

Key Studies & References Chronic urticaria: off-label doses of cetirizine - Evidence Summary (ESUOM31) - NICE

Frequently Asked Questions (FAQ)

Common questions about Cetigran (FAQ)

Q: How quickly does Cetigran usually start to have an effect?

Official drug information indicates that the onset of action is generally reported to occur within thirty minutes of taking the medication. This fast onset aligns with its pharmacological classification.

Q: Do you have to take Cetigran long term?

Regulatory agencies have approved Cetigran for both short-term, as-needed use and for long-term continuous administration. The decision regarding the duration of use is typically documented in the prescribing information.

Q: Can Cetigran affect your ability to drive or operate machinery?

Regulatory labels advise caution with activities requiring alertness, citing drowsiness and fatigue as common risks. Individuals are advised in the labeling to be aware of the effects before driving or operating machinery.

Q: Can taking Cetigran interfere with sleep?

Common side effects listed in clinical experience include drowsiness (somnolence) and fatigue. Insomnia (difficulty sleeping) has also been noted as a less frequent central nervous system side effect in official reports.

Q: How long does Cetigran stay in your system?

The primary pharmacological action of one dose typically lasts for 12 to 24 hours. Official pharmacology data indicates that when the medication is taken regularly, its concentration in the body reaches a stable level, or steady-state, within about three days.

Q: Are there any age restrictions for taking Cetigran, according to official documents?

The official eligibility profile covers a wide range of ages, including liquid formulations approved for children as young as six months under specific indications. Official documents note that special consideration or dose modification is often necessary for individuals over 65 years of age.

Q: Do you get withdrawal symptoms when stopping Cetigran?

Regulatory safety communications have noted that abruptly stopping the medication after prolonged daily use may rarely result in intense rebound itching (pruritus) or hives. This is the main post-cessation effect specifically documented in official safety information.

Q: Are there any common over-the-counter medicines that shouldn't be taken with Cetigran?

Official labels caution against co-administration with other medicines classified as Central Nervous System (CNS) depressants. This group includes some common over-the-counter pain relievers or cold and flu products, as combining them may increase the risk of dizziness and drowsiness.

Q: What happens if I accidentally take more than the recommended dose of Cetigran?

In cases where more than the recommended dose is taken, official guidance states that common symptoms may include feelings of restlessness, irritability, and increased drowsiness. In the event of an overdose, regulatory labels recommend seeking emergency medical assistance or contacting a Poison Control Center.

Q: Are there different strengths or forms of Cetigran available?

Yes, the product is formulated in several ways. Forms typically include oral tablets (in multiple strengths, such as 5 mg and 10 mg), chewable tablets, oral solution/syrup, and liquid drops.

Q: Do official sources mention any long-term side effects of Cetigran?

Safety communications primarily categorize side effects by their frequency. The only specific risk associated with long-term continuous use that is mentioned in official safety communications is the potential for rebound itching (pruritus) upon stopping the drug.

Q: Is it normal to feel a bit nauseous when first starting Cetigran?

Nausea is listed as a potential gastrointestinal side effect that can occur when taking this medicine. Some official documentation notes that taking the dose with food or focusing on simple meals may be considered for mitigation.

Q: Can Cetigran affect blood sugar levels?

Although the medication is not indicated for treating diabetes, clinical experience reports have included 'diabetes mellitus' as an adverse reaction under the Metabolic/Nutritional system classification.

Q: What is the legal classification of Cetigran (e.g., controlled substance)?

According to U.S. regulatory bodies, the drug's active ingredient, cetirizine, is not listed as a scheduled controlled substance under the Drug Enforcement Administration (DEA) guidelines.

Q: Does Cetigran contain any common allergens like lactose or gluten?

The official product monograph for Cetigran details the inactive ingredients, or excipients, used in its composition. Some oral tablet formulations are noted to contain common excipients like lactose monohydrate.

Q: Is Cetigran considered a non-addictive medication?

The drug is not classified under the U.S. Controlled Substances Act. This regulatory status is based on a substance's potential for abuse and the risk of physical or psychological dependence.

Q: Can Cetigran affect fertility?

Current scientific and regulatory information indicates that there is no evidence to suggest that taking cetirizine will reduce fertility in either men or women.

Q: Does Cetigran cause weight gain?

While not listed as a common side effect, some clinical experience reports have noted 'weight increase' as a potential systemic adverse event that can occur in some individuals.

Q: Why does the packaging say Cetigran should be used with caution in elderly patients?

Caution is officially advised in older adults primarily due to the increased likelihood of age-related reductions in kidney and/or liver function. These physiological changes may reduce the body's ability to clear the drug, potentially leading to increased exposure.

Q: What is the expected duration of the effects of one dose of Cetigran?

The pharmacological effect, which is the time the medicine is actively working in the body, typically lasts for 12 to 24 hours. This duration is consistent with its common once-daily dosing frequency.

Q: Is Cetigran known to interact with herbal supplements?

Regulatory sources generally describe the need for caution when co-administering this drug with herbal remedies or supplements that may cause similar side effects. These often include products that can cause sleepiness, dry mouth, or difficulty urinating.

Q: Does Cetigran have any warnings related to mental health changes?

Yes, official regulatory documents note that adverse reactions reported in clinical experience have included psychiatric effects. These effects may include anxiety, depression, confusion, and 'thinking abnormal'.

Q: Is Cetigran safe for people with liver disease?

For individuals with moderate or severe hepatic impairment (liver disease), official product information notes that modification of the standard adult dose is generally needed to account for potential reduced clearance.

How should Cetigran be stored and disposed of?

How to Store and Dispose of Cetigran?

Official regulatory guidelines dictate specific conditions for storing Cetigran (cetirizine dihydrochloride) to maintain product stability and effectiveness.


Storage Conditions

Cetirizine products must be stored at Controlled Room Temperature, typically 20 C to 25 C, with permitted excursions up to 30 C. It is mandatory to keep this medicine from freezing and to protect it from excess heat and moisture.

Keep the medicine in its original container, which must be tightly closed. Liquid forms may require additional protection from light.


Handling and Disposal

The medicine must always be stored out of the sight and reach of children. Do not use the product after the printed expiry date. Unused or expired Cetigran must not be thrown away via wastewater or household waste; disposal must adhere strictly to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cetigran found in:

A-Z Index: